Neurovance
Cambridge
Massachusetts
United States
11 articles about Neurovance
-
Otsuka Pharma Plunks Down $250 Million for Cambridge Biotech Neurovance for Late-Stage Ready ADHD Drug
3/3/2017
-
Neurovance Announces The Appointment Of Brian Goff As Chief Operating Officer As The Company Prepares For The Next Stage Of Growth And Development
12/14/2016
-
Neurovance Announces Positive Centanafadine Phase 2b Results For Adult ADHD, And Plans For Phase 3 Trials
7/27/2016
-
Neurovance Appoints Jeff Bailey To Chair Its Board Of Directors
1/8/2016
-
Neurovance Announces Series Of Three Clinical Trials To Support Advanced Development Of Centanafadine (CTN) In Adult ADHD
1/7/2016
-
Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential For Centanafadine Compared To Stimulants Used For Adult ADHD
12/11/2014
-
Neurovance Completes Enrollment In Human Abuse Liability Study For Centanafadine (Formerly Called EB-1020) For Adult ADHD
8/7/2014
-
Neurovance Appoints Brigitte Robertson, MD, Vice President, Clinical Development
8/5/2014
-
Neurovance’s EB-1020 SR For Adult ADHD Shows Stimulant-Like Efficacy And Good Tolerability In Phase 2a Trial
5/9/2014
-
Cambridge Startup Neurovance Wraps Up $6.3 Million Funding Round
4/3/2014
-
Neurovance Says Interim Data From Phase 2a Pilot Study Of EB-1020 SR Shows Stimulant-Like Efficacy, But With Lower Risk Of Abuse, For Adult ADHD
1/9/2014